Previous 10 | Next 10 |
home / stock / bovnf / bovnf news
Trial investigates BI-1910 as single agent and in combination with pembrolizumab Exploratory expansion cohorts planned in hepatocellular carcinoma and non-small cell lung cancer BioInvent now has five drug candidates in six clinical trials, reflecting productivity of technology platform...
LUND, SE / ACCESSWIRE / November 3, 2023 / BioInvent International (STO:BINV): Preliminary data from Phase 1 part show encouraging early efficacy signals Robust partial response in one patient with gastrointestinal tumor; 7 cases of stable disease Favorable safety profile with no dose-...
Broad anti-tumor activity in preclinical studies, activating T cells and NK cells FcyR-independent antitumor activity Data support start of Phase 1 trial in H2 2023, further expanding BioInvent's pipeline LUND, SE / ACCESSWIRE / October 31, 2023 / ("BioInvent") (Nasdaq Stockholm:B...
LUND, SE / ACCESSWIRE / October 26, 2023 / BioInvent International (STO:BINV) "In the third quarter of 2023, BioInvent achieved a significant landmark with the recruitment of the first patient to the BI-1808 single agent Phase 2a study. BI-1808 can potentially become a novel checkpoint inhibi...
LUND, SWEDEN / ACCESSWIRE / October 25, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts and the press to a presentation of the interim report January- September 2023 at 2:00 pm on Thursday October 26. The re...
LUND, SE / ACCESSWIRE / October 10, 2023 / BioInvent International (STO:BINV) The Phase 1 Part B will evaluate the combination of BT-001 and pembrolizumab in solid tumors, including melanoma. LUND, SWEDEN / ACCESSWIRE / October 10, 2023 / BioInvent International AB ("BioInvent") (Nasdaq Sto...
LUND, SE / ACCESSWIRE / September 27, 2023 / BioInvent International (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it will hold two poster presentations on its anti-tumor n...
LUND, SWEDEN / ACCESSWIRE / September 22, 2023 / BioInvent International (STO:BINV) Strong interim safety data on BI-1808 as single agent reported in June 2023 Next data readout, from Phase 1 combination part of trial, to come in H1 2024 BioInvent International AB ("BioInvent") (Nasda...
LUND, SE / ACCESSWIRE / September 08, 2023 / BioInvent International (STO:BINV) First patient has been enrolled for treatment with subcutaneous BI-1206 in solid tumors Subcutaneous formulation will significantly improve convenience of dosing regimen BioInvent International AB ("BioIn...
2023-08-30 11:48:12 ET More on BioInvent International BioInvent potential cancer drug BI-1808 shows safety in interim phase 1/2a trial data Exelixis to pay BioInvent $25M upfront to discover antibodies for cancer therapies Earnings data for BioInvent International ...
News, Short Squeeze, Breakout and More Instantly...
Bioinvent Ab Company Name:
BOVNF Stock Symbol:
OTCMKTS Market:
First data for the SC arm : 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients. Further updates from the IV arm; a fifth CR has been observed, adding to a total of 5 CR, 1 PR and 6 SD out of 17 evaluable patients. Data to be presented at ...
LUND, SWEDEN / ACCESSWIRE / May 3, 2024 / BioInvent International (STO:BINV) The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to elect Laura Lassouw-Polman as new Board member, to re-elect the Board members Natalie Berner, Kristoffe...
The two poster presentations will report - first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy arm combination data from the Phase 1/2a study with BI-1206 in combin...